Schubert & Co’s AtriCure ATRC Stock Holding History

Schubert & Co’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1	Closed	-$42	–	147
2023 Q1	$42	Sell	1 -9	-90%	-$373	﹤0.01%	1640
2022 Q4	$444	Buy	10 +4	+67%	+$167	﹤0.01%	1414
2022 Q3	$0	Buy	6 +1	+20%	+$46	﹤0.01%	1369
2022 Q2	$0	Buy	+5	New	+$237	﹤0.01%	1434

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Schubert & Co's ATRC Position: Q2 2023 in Review

Schubert & Co sold out of AtriCure (ATRC) in Q2 2023, closing a stake of 1 share — an estimated $42 sold.

Schubert & Co first reported a position in ATRC in Q2 2022 and held it in 4 quarters. The position peaked at $444 in Q4 2022. 223 funds tracked by Wall St. Rank hold ATRC as of Q2 2023.

Schubert & Co reported no remaining AtriCure position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 1 AtriCure share in Q2 2023, an estimated $42.
Schubert & Co first reported a position in AtriCure in Q2 2022 and held it in 4 quarters.
Schubert & Co's AtriCure position peaked at $444 in Q4 2022.
223 funds tracked by Wall St. Rank held AtriCure as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.